Spero Therapeutics (SPRO) Insider JR Buys 20,000 Shares

Insider Buying and Selling at Spero Therapeutics, Inc.

Pottage John JR bought 20,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO) on June 23, 2026. This purchase added to a notable cluster of transactions by company leaders on the same day.

Stock Performance and Recent Trading Levels

The shares recently changed hands at $2.02, sitting well above their 52-week low of $1.08 and below the high of $3.08. The stock trades near its 50-day moving average of $1.26 while tracking below its 200-day moving average of $2.16. With a spot price of $2.02, market participants continue to watch how the equity moves ahead of upcoming financial updates.

Recent Earnings and Financial Health

The clinical-stage firm posted annual revenue of $46.99 million alongside a net margin of 15.7% and a return on equity of 19.2%. Its earnings per share stand at $0.14, and the price-to-earnings ratio rests at 8.14. Investors can look toward the company's next financial results scheduled for release on November 12, 2026, for further updates on its drug candidate pipeline.

Broad Insider Buying Activity

Several other leaders also stepped up their investments on June 23, 2026. Frank Thomas acquired 20,000 shares, while Cynthia Smith picked up another 20,000 shares. Milind Deshpande also purchased 20,000 shares, and Vink Patrick V.J.J. bought 10,000 shares. Kathleen Tregoning added to the total by acquiring 10,000 shares in a separate transaction on the same date.

Analysts Set New Price Targets

HC Wainwright & Co. maintained its Buy rating on the stock while raising its price target from $5.00 to $6.00 on September 14, 2026. The broader analyst community holds a consensus Buy recommendation for the equity, backed by two analyst opinions pointing to a mean target price of $5.00.

Inside Spero Therapeutics Operations

Spero Therapeutics, Inc. focuses on creating medicines for multi-drug resistant bacterial infections and rare diseases. Headquartered in Cambridge, Massachusetts, the firm develops treatments such as Tebipenem HBr for complicated urinary tract infections. Executive purchases like the one made by Pottage John JR offer a look at how leadership allocates capital within the biotechnology sector.

What to Watch at Spero Therapeutics, Inc.

Observers will monitor upcoming regulatory updates, the upcoming earnings report on November 12, 2026, and further SEC filings to track executive sentiment. As always, insider transactions provide a look at past decisions rather than a guarantee of future stock movements.